Holen Sie sich die Stockscreener-App
7.51
1.18%
-0.09
Handel nachbörslich:
7.35
-0.16
-2.13%
Schlusskurs vom Vortag:
$7.60
Offen:
$7.5
24-Stunden-Volumen:
557.34K
Relative Volume:
0.91
Marktkapitalisierung:
$232.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.25M
KGV:
-6.3322
EPS:
-1.186
Netto-Cashflow:
$-22.80M
1W Leistung:
+2.32%
1M Leistung:
+11.09%
6M Leistung:
+215.55%
1J Leistung:
+44.70%
1-Tages-Spanne:
$7.19
$7.6928
1-Wochen-Bereich:
$7.15
$8.76
52-Wochen-Spanne:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Vergleichen Sie SGMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.51 | 249.60M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Eingeleitet | Wedbush | Outperform |
| 2025-08-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-12-06 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Herabstufung | Goldman | Buy → Neutral |
| 2024-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-25 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-08 | Eingeleitet | Goldman | Buy |
| 2023-08-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-08 | Eingeleitet | Piper Sandler | Overweight |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - The Manila Times
Sagimet Biosciences Inc. Announces Participation in Upcoming Investor Conferences - Quiver Quantitative
What technical models suggest about Sagimet Biosciences Inc.’s comeback2025 Key Lessons & Safe Capital Allocation Plans - newser.com
3 Investor Conferences: Sagimet Biosciences to Present Oct–Nov; Fireside chats with 90-day replays - Stock Titan
Phase III met all endpoints: Ascletis completes pre‑NDA consultation with NMPA and plans NDA submission - Stock Titan
What does recent volatility data suggest for Sagimet Biosciences Inc.Weekly Gains Report & Accurate Intraday Trade Tips - newser.com
Will Sagimet Biosciences Inc. stock deliver shareholder value2025 Retail Activity & Fast Exit Strategy with Risk Control - newser.com
Is Sagimet Biosciences Inc. forming a reversal patternJuly 2025 Opening Moves & Capital Protection Trade Alerts - newser.com
Will Sagimet Biosciences Inc. (0O2) stock justify high valuationMarket Sentiment Report & Reliable Price Action Trade Plans - newser.com
Is a relief rally coming for Sagimet Biosciences Inc. holders2025 Biggest Moves & Low Risk High Win Rate Picks - newser.com
Sagimet Biosciences Inc. stock retracement – recovery analysisJuly 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
Sagimet Biosciences (NASDAQ:SGMT) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Using flow based indicators on Sagimet Biosciences Inc.July 2025 Decliners & Capital Efficient Trade Techniques - newser.com
Has Sagimet Biosciences Inc. found a price floorAnalyst Upgrade & Stock Market Timing Techniques - newser.com
Developing predictive dashboards with Sagimet Biosciences Inc. dataWeekly Profit Summary & Reliable Intraday Trade Alerts - newser.com
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN
Viking, Genfit, Sagimet jump on Novo- Akero deal (AKRO:NASDAQ) - Seeking Alpha
Sagimet Biosciences' (SGMT) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Will Sagimet Biosciences Inc. benefit from macro trends2025 Key Lessons & Smart Money Movement Tracker - newser.com
Denifanstat Advances: Sagimet Builds Momentum Toward 2026 Readouts (NASDAQ:SGMT) - Seeking Alpha
Sagimet Biosciences to Present Positive Results for Denifanstat in Advanced Fibrosis at AASLD 2025 - Quiver Quantitative
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025 - GlobeNewswire
≥2‑Stage Fibrosis Improvement: Sagimet denifanstat data to be presented at AASLD 2025 - Stock Titan
Using Ichimoku Cloud for Sagimet Biosciences Inc. technicalsPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Why analysts recommend Sagimet Biosciences Inc. (0O2) stock2025 Geopolitical Influence & Smart Money Movement Tracker - newser.com
Using data tools to time your Sagimet Biosciences Inc. exit2025 Risk Factors & Daily Stock Trend Watchlist - newser.com
Is Sagimet Biosciences Inc. stock ready for a breakoutJuly 2025 Final Week & Low Drawdown Trading Strategies - newser.com
Sagimet Biosciences (NASDAQ:SGMT) Given “Buy” Rating at Canaccord Genuity Group - Defense World
Risk vs reward if holding onto Sagimet Biosciences Inc.Trade Entry Summary & Fast Gaining Stock Strategy Reports - newser.com
Has Sagimet Biosciences Inc. formed a bullish divergenceExit Point & Safe Entry Trade Signal Reports - newser.com
Applying big data sentiment scoring on Sagimet Biosciences Inc.Gap Down & Weekly Market Pulse Alerts - newser.com
Canaccord Genuity Maintains Sagimet Biosciences (SGMT) Buy Recommendation - Nasdaq
Canaccord Genuity Group Reiterates Buy Rating for Sagimet Biosciences (NASDAQ:SGMT) - MarketBeat
Buy Rating for Sagimet Biosciences: Promising Clinical Developments and Synergistic Therapy Potential - TipRanks
Goldman Sachs Group Inc. Sells 109,464 Shares of Sagimet Biosciences Inc. $SGMT - Defense World
Sagimet Biosciences Inc Stock Analysis and ForecastInsider Selling Patterns & Minimal Investment Portfolio Growth - earlytimes.in
Published on: 2025-10-01 08:26:59 - newser.com
Sagimet Biosciences Inc. Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination - MarketScreener
Sagimet announces dosing in Phase 1 PK trial of denifanstat with resmetirom - TipRanks
Sagimet Biosciences Initiates Phase 1 Trial for Combination Therapy Targeting Metabolic Dysfunction-Associated Steatohepatitis - Quiver Quantitative
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sagimet Biosciences Inc-Aktie (SGMT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 21 '25 |
Sale |
9.13 |
8,277 |
75,607 |
106,936 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 21 '25 |
Sale |
9.13 |
10,780 |
98,471 |
183,726 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):